1. Date of download: 7/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy J Am Coll Cardiol. 2016;67(20):2411-2418. doi:10.1016/j.jacc.2016.02.066 Primary Endpoint in the Overall Patient Population TACT (Trial to Assess Chelation Therapy) Kaplan-Meier estimates of the primary composite endpoint: edetate disodium (EDTA) chelation therapy versus placebo (2). The primary endpoint was a composite of death from any cause, reinfarction, stroke, coronary revascularization, or hospitalization for angina. CI = confidence interval. Figure Legend:

2. Date of download: 7/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy J Am Coll Cardiol. 2016;67(20):2411-2418. doi:10.1016/j.jacc.2016.02.066 Primary Endpoint in Patients With Diabetes Kaplan-Meier estimates of the primary composite endpoint: EDTA chelation therapy versus placebo, subset of patients with diabetes (19). Abbreviations as in Figure 1. Figure Legend:

3. Date of download: 7/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy J Am Coll Cardiol. 2016;67(20):2411-2418. doi:10.1016/j.jacc.2016.02.066 Heavy Metals as a Risk Factor for Atherosclerotic Cardiovascular Disease and the Benefits of Chelation Therapy Major sources and routes of exposure, mechanisms at the molecular and cellular level, responses at the tissue and organ level, and subclinical and clinical cardiovascular effects on the basis of experimental and epidemiological evidence are shown for lead and cadmium. Arrows denote direction of flow. Na2EDTA = disodium ethylene diamine tetra acetic acid; NO = nitric oxide; TACT = Trial to Assess Chelation Therapy. Figure Legend: